We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site

IsoPlexis Proteomic Product Suite for Tumor Resistance

Learn how IsoPlexis’ single-cell signaling reveals coordinated signals from tumor cells driving resistance.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

Overcoming challenges in tumor resistance
Informing targeted combination therapy to overcome resistance in glioblastoma (GBM)
Resolving tumor heterogeneity to reveal independent trajectories of drug tolerance
Early signs of drug resistance in rare melanoma cells
Elucidating mechanisms of tumorigenesis
A Deeper Look

More about this

Overcoming Challenges in Tumor Resistance

A major challenge in the field of cancer immunology is that tumor cells can develop resistance to targeted therapies.

Download this App Note to learn how IsoPlexis helps researchers understand the impacts of their therapies earlier in development and the mechanisms behind therapy resistance in oncology research.

Get the